Abetimus
A synthetic drug used in the treatment of systemic lupus erythematosus
| Abetimus | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Abetimus is a synthetic oligonucleotide drug designed for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease characterized by the production of autoantibodies against the body's own tissues. Abetimus is specifically engineered to reduce the levels of anti-double-stranded DNA antibodies, which are implicated in the pathogenesis of SLE.
Mechanism of Action
Abetimus functions by acting as a decoy for anti-DNA antibodies. It is composed of four double-stranded DNA sequences attached to a polyethylene glycol (PEG) backbone. These sequences mimic the structure of native DNA, allowing abetimus to bind to circulating anti-DNA antibodies. This binding reduces the availability of these antibodies to interact with the body's own DNA, thereby decreasing the inflammatory response and tissue damage associated with SLE.
Clinical Use
Abetimus is used as a therapeutic agent in patients with systemic lupus erythematosus who have high levels of anti-DNA antibodies. By lowering these antibody levels, abetimus can help to manage the symptoms of SLE and prevent flares. However, its use is limited to specific cases and it is not a first-line treatment.
Development and Approval
Abetimus was developed as a novel approach to treating autoimmune diseases by targeting specific autoantibodies. Despite its innovative mechanism, the clinical development of abetimus faced challenges, and it has not been widely adopted in clinical practice. The drug's approval status and availability may vary by region.
Side Effects
The administration of abetimus can lead to side effects, which may include injection site reactions, allergic reactions, and potential immunosuppression. Patients receiving abetimus should be monitored for these adverse effects, and the treatment should be adjusted accordingly.
Related pages
Gallery
-
Structure of Abetimus
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
